IQVIA

Market Reflection Report

Nov 2023

10th December

© 2023. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States,
the European Union, and various other countries.
 IPM Overview
TSA SSA
Growth %%

80 60
60 2020-21
40
40 2021-22
20
20 2022-23
0 0
-20 -20
Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov

TSA IPM Trends (Value Rs. 200,507 Crs) – MAT Nov'23 SSA IPM Trends (Value Rs. 169,705 Crs) – MAT Nov'23

+4%
10% +3%
10%
MAT
212,224 MAT
Month 179,315
192,105 Month
180,671 162,840
153,074
152,433
130,554

13,448 15,122 17,392 18,002 11,474 12,823 14,738 15,232

2020 2021 2022 2023 2020 2021 2022 2023

• TSA valued at Rs. 212,224 Cr with growth of 10% as of MAT Nov'23 and Rs 18,002 Cr for Nov'23 month with growth of 4%
• SSA valued at Rs. 179,315 Cr with growth of 10% as of MAT Nov'23 and Rs 15,232 Cr for Nov'23 month with growth of 3%

IQVIA TSA & SSA Dataset Nov'23 1

 Among top 5 contributing therapies, Cardiac & Gastro posted
highest growth
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)

13 24 20 17
IPM 18,002 4 12 10 5 7 6 9 4 IPM

12 17 13 12 14
Cardiac 2,230 11 9 9 11 9 8 5
52 51 Crdiac
23 26 9 12 24
Anti-Infectives 2,098 -2 -1 -5 -2 3 AI

Gastro 1,770 24 15 18
11 6 7 6 4 7 8 11 5 Gastro
56 50
Respiratory 1,747 21 30 16
10 -5 -4 9 3 Respi
-7 -6
13 9 10
Anti Diabetic 1,562 7 7 8 5 6 6 4 2 ADB
4
Pain 1,415 16 26 22 15 17
0 12 6 7 5 10 3 Pain
17 19
Vmn 1,353 11 12 9 7 7
7 5 7 2 VMN
1
11 12 11
Derma 1,234 6 7 6 8 8 6 8
3
-2
Neuro 1,079 13 12 16 11 12 15 Derma
9 7 9 7 8 6
Neuro
Gynaec. 843 15 11 17 14
10 8 4 10 8 5
4 0 Gynaec
Antineoplast 468 23 23 28 29 27 16 18 27 23 24 28 29
Antineoplast
16 15 19 16 18 16 15 18
13 13 12 8
Urology 377
Ophthal
Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov

IQVIA TSA & SSA Dataset Nov'23 2

Therapy sorted on Month
 Top Companies #1-10 Market Share Trend
9

Val Nov'23 MS Nov'23

8 SUN* 1,412 7.84

ABBOTT* 1,105 6.14

CIPLA 1,068 5.93

7
(MANKIND) 787 4.37

(ALKEM*) 721 4.01

6
INTAS* 638 3.54
(MACLEODS) 612 3.40
5
TORRENT 611 3.40
LUPIN 610 3.39
4 (ARISTO*) 529 2.94

2
Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23

• Sun*, Abbott*, Cipla, Intas*, Torrent & Lupin have shown improvement in MS for Nov'23 as compared to Oct’23
• Mankind, Alkem*, Macleods & Aristo* reflected dip in MS for Nov'23 as compared to Oct'23

IQVIA TSA & SSA Dataset Nov'23 3

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

SUN* 1,412 7 103 SUN* 1,201 6 103

ABBOTT* 1,105 5 101 ABBOTT* 949 5 102
CIPLA 1,068 9 105 CIPLA 911 10 106
MANKIND 787 1 98 MANKIND 714 2 99
Month

Month
ALKEM* 721 3 100 ALKEM* 633 4 101
INTAS* 638 7 103 MACLEODS 543 4 101
MACLEODS 612 4 100 TORRENT 543 7 103

TORRENT 611 6 102 LUPIN 526 2 98

LUPIN 610 1 98 INTAS* 516 5 102

3 99 ARISTO* 478 2 99
ARISTO* 529

SUN* 16,371 10 100 SUN* 13,902 9 99

ABBOTT* 13,134 11 100 ABBOTT* 11,241 11 101
CIPLA 11,418 11 101 CIPLA 9,654 12 101
MANKIND 9,333 13 102 MANKIND 8,425 13 103
MAT

101 101

MAT
ALKEM* 8,618 12 ALKEM* 7,486 12
INTAS* 7,420 14 103 TORRENT 6,355 10 100
LUPIN 7,244 8 97 MACLEODS 6,303 14 104
TORRENT 7,209 11 100 LUPIN 6,183 7 97
MACLEODS 7,110 14 104 INTAS* 6,036 13 103
ARISTO* 6,294 15 104 ARISTO* 5,699 14 104

• TSA : Cipla has posted highest growth for the month followed by Sun* & Intas* while on MAT level, Aristo* is the fastest growing company

• SSA : Cipla has posted highest growth followed by Torrent on Month while on MAT , Macleods & Aristo* have reflected the highest growth

IQVIA TSA & SSA Dataset Nov’23

4
 Top Companies #11-20 Market Share Trend
3.0

2.8
Val Nov'23 MS Nov'23
2.6 DRL 519 2.88

2.4 ZYDUS* 510 2.84

(GSK*) 432 2.40
2.2
GLENMARK 383 2.12
2.0 (EMCURE*) 351 1.95

1.8 (IPCA) 348 1.93

USV 345 1.92
1.6
SANOFI* 301 1.67
1.4 (MICRO*) 287 1.59

1.2 ALEMBIC 284 1.57

1.0

0.8

0.6
Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23

• DRL, Zydus*, Glenmark, USV, Sanofi* & Alembic have shown improvement in MS for Nov'23 as compared to Oct’23
• GSK*, Emcure*, IPCA & Micro* reflected dip in MS for Nov'23 as compared to Oct'23
.

IQVIA TSA & SSA Dataset Nov'23 5

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

1 97 DRL 452 3 100

DRL 519
1 98 ZYDUS* 419 2 98
ZYDUS* 510
-4 93 GSK* 346 -5 92
GSK* 432
6 103 GLENMARK 339 8 104
GLENMARK 383
Month

Month
0 97 USV 313 7 104
EMCURE* 351
10 107 IPCA 301 12 108
IPCA 348
6 102 EMCURE* 293 1 97
USV 345
4 100 ALEMBIC 257 4 101
SANOFI* 301
-6 91 MICRO * 245 -6 91
MICRO * 287
4 100 SANOFI* 227 0 97
ALEMBIC 284

DRL 6,091 7 97 DRL 5,256 8 98

ZYDUS* 6,069 9 98 ZYDUS* 4,934 8 98
GSK* 5,187 5 95 GSK* 4,196 6 96
GLENMARK 4,304 11 101 GLENMARK 3,807 12 102
MAT

98 10 100

MAT
EMCURE* 4,253 9 USV 3,650
IPCA 4,120 14 103 IPCA 3,556 13 103
USV 4,087 10 99 EMCURE* 3,520 9 99
MICRO * 3,442 6 96 MICRO * 2,951 7 97
SANOFI* 3,411 6 96 ALEMBIC 2,861 10 100
PFIZER* 3,267 1 92 SANOFI* 2,574 2 93

• TSA & SSA : In both the audits, IPCA has posted the highest growth on month and for MAT, IPCA followed by Glenmark has posted highest growth

IQVIA TSA & SSA Dataset Nov’23

6
 Top Companies #21-30 Market Share Trend
1.7
Val Nov'23 MS Nov'23
1.6 283 1.57
PFIZER*
1.5 ERIS* 189 1.05

JB PHARMA* 186 1.03

1.4
(FDC) 160 0.89
1.3
(HIMALAYA) 142 0.79
1.2 AJANTA 133 0.74

1.1 (CADILA) 126 0.70

LA RENON 124 0.69

1.0
(FRANCO) 106 0.59
0.9 106 0.59
(INDOCO*)
0.8

0.7

0.6

0.5
Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23

• Pfizer*, Eris*, JB Pharma*, Ajanta & La Renon have shown improvement in MS for Nov'23 as compared to Oct’23
• FDC, Himalaya, Cadila, Franco & Indoco* have reflected dip in MS for Nov'23 as compared to Oct'23

IQVIA TSA & SSA Dataset Nov'23 7

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

94 PFIZER* 224 -2 94
PFIZER* 283 -3
102 JB PHARMA* 165 8 105
ERIS* 189 5
7 104 ERIS* 163 5 102
JB PHARMA* 186
-1 95 FDC 146 -2 95
FDC 160
Month

Month
-2 95 HIMALAYA 125 -4 93
HIMALAYA 142
0 97 AJANTA 118 1 98
AJANTA 133
-1 95 CADILA 104 1 97
CADILA 126
16 112 LA RENON 101 15 111
LA RENON 124
-18 79 FRANCO 97 -18 79
FRANCO 106
-2 95 INDOCO* 95 -2 95
INDOCO* 106

ALEMBIC 3,186 100 PFIZER* 2,557 3 93

10
ERIS* 2,223 98 FDC 2,035 13 102
8
FDC 2,217 102 ERIS* 1,929 9 99
13
JB PHARMA* 2,182 106 JB PHARMA* 1,919 16 106
17
MAT

95 4 95

MAT
HIMALAYA 1,702 HIMALAYA 1,515
5
AJANTA 1,595 102 AJANTA 1,411 12 102
13
CADILA 1,581 98 FRANCO 1,322 4 94
8
FRANCO 1,423 94 CADILA 1,299 8 98
4
LA RENON 1,419 111 INDOCO* 1,166 3 93
23
INDOCO* 1,291 94 LA RENON 1,150 22 111
3

• TSA & SSA: La Renon has posted the highest growth for the month & MAT while JB Pharma* on a MAT was second fastest growing company in both the audits

IQVIA TSA & SSA Dataset Nov’23

8
 Top Companies #31-40 Market Share Trend
0.64 Val Nov'23 MS Nov'23
0.62 (HETERO*) 104 0.58
0.60 (BLUE CROSS) 102 0.57
0.58 (CORONA) 101 0.56

0.56 (P&G HLTH) 93 0.52

0.54 SYSTOPIC 92 0.51

0.52 (WIN MEDICARE) 80 0.45

FOURRTS 79 0.44
0.50
(MEDLEY) 79 0.44
0.48
H&H 77 0.43
0.46
JANSSEN 72 0.40
0.44
0.42
0.40
0.38
0.36
Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23

• Systopic, Fourrts & Janssen have shown improvement in MS for Nov'23 as compared to Oct’23
• H&H has maintained MS in the month of Nov’23
• Hetero*, Blue Cross, Corona, P&G Hlth, Win Medicare & Medley reflected dip in MS for Nov'23 as compared to Oct'23

IQVIA TSA & SSA Dataset Nov'23 9

 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

HETERO* 104 8 105 BLUE CROSS 93 -1 96

BLUE CROSS 102 -1 95 CORONA 86 7 103
CORONA 101 6 102 P&G HLTH 85 -10 87
P&G HLTH 93 -10 87 SYSTOPIC 82 10 107
Month

Month
SYSTOPIC 92 10 106 HETERO* 80 1 98
WIN MEDICARE 80 -1 95 MEDLEY 74 1 98
FOURRTS 79 11 108 WIN MEDICARE 70 0 97
MEDLEY 79 0 97 FOURRTS 68 11 107
H&H 77 0 97 H&H 66 -1 95
JANSSEN 72 10 106 APEX 59 0 96

BLUE CROSS 1,256 8 98 BLUE CROSS 1,146 8 98

CORONA 1,238 18 107 P&G HLTH 1,075 4 94
HETERO* 1,216 19 108 CORONA 1,042 18 107
P&G HLTH 1,182 4 94 HETERO* 973 18 107
MAT

100 5 95

MAT
SYSTOPIC 1,062 10 MEDLEY 954
MEDLEY 1,018 5 95 SYSTOPIC 947 10 99
WIN MEDICARE 942 9 99 WIN MEDICARE 822 10 100
H&H 902 4 95 H&H 777 3 93
FOURRTS 890 14 103 FOURRTS 765 12 102
APEX 828 3 94 APEX 733 3 94

• TSA: Fourrts shows the highest growth at month level, while for MAT, Hetero* has posted highest growth followed by Corona
• SSA: Fourrts shows the highest growth at month level, while for MAT, Corona & Hetero* have posted highest growth

IQVIA TSA & SSA Dataset Nov’23

10
 Top Companies #41-50 Market Share Trend
0.42
0.41
0.40 Val Nov'23 MS Nov'23
0.39 BHARAT SERUM 68 0.38
0.38
(APEX) 68 0.38
0.37
0.36 MEYER 67 0.37
0.35 ASTRA 63 0.35
0.34
0.33 (WALLACE) 62 0.34
0.32 SAMARTH 60 0.33
0.31
CENTAUR 58 0.32
0.30
0.29 (RAPTAKOS) 57 0.32
0.28 MSD* 57 0.32
0.27
0.26
NOVARTIS* 56 0.31

0.25
0.24
0.23
0.22
0.21
Nov’22 Dec’22 Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23

• Bharat Serum, Astra, Centaur, MSD* & Novartis* have shown improvement in MS for Nov'23 as compared to Oct’23
• Meyer & Samarth has maintained MS in the month of Nov’23
• Apex, Wallace & Raptakos reflected dip in MS for Nov'23 as compared to Oct'23

IQVIA TSA & SSA Dataset Nov'23 11

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

6 MEYER 56 2 98
BHARAT SERUM 68 102
0 WALLACE 56 2 99
APEX 68 96
2 CENTAUR 54 -1 95
MEYER 67 99
27 RAPTAKOS 50 -2 95
ASTRA 63 123
Month

Month
1 BHARAT SERUM 49 5 102
WALLACE 62 97
17 BOEHRINGER 46 -9 88
SAMARTH 60 113
-2 JANSSEN 45 -8 89
CENTAUR 58 94
-2 PHARMED 44 0 97
RAPTAKOS 57 95
-10 DABUR 43 -9 88
MSD* 57 87
-17 NOVARTIS* 42 -22 76
NOVARTIS* 56 80

BHARAT SERUM 825 2 92 WALLACE 727 9 99

MEYER 824 11 100 MEYER 705 11 101
JANSSEN 818 3 93 RAPTAKOS 642 6 96
WALLACE 812 10 99 BOEHRINGER 596 -5 87
MAT

MAT
RAPTAKOS 738 8 98 BHARAT SERUM 590 91
MSD* 732 -2 88 CENTAUR 570 5 95
NOVARTIS* 714 -6 85 JANSSEN 557 -1 90
BOEHRINGER 711 -5 86 NOVARTIS* 542 -5 86
SAMARTH 688 24 112 PHARMED 539 13 103
ASTRA 670 20 108 MSD* 524 -6 85

• TSA: Astra & Samarth are the fastest growing company

• SSA: Bharat Serum shows the highest growth at month level, while for MAT, Pharmed is the fastest growing company followed by Meyer

IQVIA TSA & SSA Dataset Nov’23

12
 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

22 0.45 0.21
FORACORT 81 CALPOL 39 -3
-2 0.39 0.20
AUGMENTIN 70 DOLO 36 -11
2 0.38 0.20
GLYCOMET-GP 68 SHELCAL 36 0
Top 1-10

Top 21-30
-11 0.37 0.20
MIXTARD 67 ROSUVAS 36 16
2 0.31 0.19
MONOCEF 56 MOXIKIND-CV 35 5
28 0.30 0.19
UDILIV 54 LEVIPIL 34 10
7 0.30 0.19
THYRONORM 53 DEXORANGE 34 -13
12 0.28 0.19
PAN 51 ULTRACET 33 0
-11 0.28 0.18
CLAVAM 50 DUPHASTON 33 11
16 0.28 0.18
BUDECORT 50 RANTAC 33 12
0.27 32 0.18
DUOLIN 49 13 ECOSPRIN-AV 8
LIV-52 47 -1 0.26 ACILOC 32 -1 0.18
0.26 0.18
Top 11-20

AZITHRAL 46 4 NOVOMIX 32 -18

Top 31-40
LANTUS 46 -17 0.25 VOLINI 31 -3 0.17
BETADINE 45 -7 0.25 PANTOP 31 10 0.17
ZERODOL-SP 45 20 0.25 CILACAR 30 3 0.17
PAN-D 44 16 0.25 TELMA-H 30 23 0.17
RYZODEG 43 13 0.24 ASTHALIN 30 -2 0.16
MANFORCE 40 -4 0.22 PREVENAR-13 29 3 0.16
TELMA 40 9 0.22 T-BACT 29 -14 0.16

• Foracort is the topmost brand with 81 Crs of sales & MS of ~0.45% for the month

• Among top 10 brands, Udiliv has shown highest growth followed by Foracort for the month

IQVIA TSA & SSA Dataset Nov’23

13
 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Nov'23 Month (in comparison to Oct'23 Month)

• Foracort has gained No 1 position at month level with a growth of 22%

• Amongst the top 10 Brands, highest growth is observed by Udiliv with a growth of 28%
• Thyronorm gained 3 ranks to secure 7th position with a growth of 7.43%
• Udiliv gained 6 ranks to secure 6th position with a growth of 28%
• Azithral & Lantus gained 1 rank each to secure 13th & 14th position, respectively
• Glycomet-GP, Telma & Shelcal gained 2 ranks to secure 3rd ,20th & 23rd position with a growth of 2%, 9% & -0.1%, respectively
• Rosuvas gained 7 ranks to secure 24th position with a growth of 16%
• Budecort, Duolin & Manforce gained 9 ranks each to reach 10th, 11th & 19th position with a growth of 16%, 13% & -3.7%, respectively

IQVIA TSA & SSA Dataset Nov’23

14
 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Nov'23 (in comparison to Oct'23), among the In the month of Nov'23 (in comparison to Oct'23), among
Top 25 companies the Top 25 companies
• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%
• Intas*, Emcure*, Sanofi*, Eris* & JB Pharma improved by 1 • Torrent* & Alembic improved by 1 rank each to reach 7th & 18th
rank each to reach 6th, 15th, 18th, 22nd & 23rd positions, positions, respectively
respectively • Lupin, USV & JB Pharma* improved by 2 ranks each to reach
• Torrent* improved by 2 ranks to reach 8th position 8th, 15th & 22nd positions, respectively

As per MAT Nov'23 (in comparison to MAT Oct'23), among
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Eris* improved by 1 ranks to reach & 22nd position
As per MAT Oct'23 (in comparison to MAT Oct'23), among
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• All companies maintained their ranks for MAT Nov’23

IQVIA TSA & SSA Dataset Nov’23

15
 Indian / MNC trends % Growth Over Same Month Last Year Indian MNC

30
26
25
21
20 17
18
Month Growth

14 15
15 14
13
11
10 9 9
7 7 8
6 6 6 4
9 4
5 2 3 3

0 3
DEC’22 JAN’23 FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23 NOV’23

Value (Rs. Crs)

Indian MNC

17,188 16,617 16,690 17,157 17,952 17,233 16,618 17,859 18,712 19,200 18,996 18,002
Share in IPM

14,240 13,804 13,857 14,142 14,864 14,267 13,778 14,832 15,580 16,003 15,821 14,931

2,948 2,813 2,834 3,015 3,089 2,966 2,840 3,026 3,132 3,197 3,175 3,071

DEC’22 JAN’23 FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23 NOV’23

• Indian companies has registered growth of 4% whereas MNC’s registered a growth of 3% for the month

IQVIA TSA & SSA Dataset Nov'23 16

 Acute / Chronic Trends
ACUTE CHRONIC
30 27
25 22
20
20 18
15 13 15
Growth (%)

15 13
11 11 10
12 9 8 9 9
10 6
3 4
5 5
0 2
0
-5
DEC’22 JAN’23 FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23 NOV’23

Gwth %
-0.3% -3% 1% -7% 6%
Top 5 TC 4s

274 255
Value (Rs 222
193 190
Crs)

GLIMEPIRIDE+METFORM. COUGH PREP. ETHICALS AMOXY. & CLAV. SOLIDS INTER.-ACTING+FAST ACTING FOOD SUPPLEMENTS

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 68 GLENMARK 44 GSK* 51 ABBOTT* 141 APEX 28

LUPIN 29 FRANCO 11 ALKEM* 34 LUPIN 25 ALKEM* 27

SUN* 27 DRL 31 MANKIND 33 CIPLA 10 SUN* 22

• Acute has shown growth of 2% whereas Chronic has shown growth of 6% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Nov'23 17
 Top Therapy Trends
TSA

Value_Nov'23 (Rs. Crs) % Gwth SPLY Value_Nov'23 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 114 7 J01C0G AMOXY. & CLAV. SOLIDS 222 1

C02C04 TELMISARTAN 102 3 J01D0C CEFTRIAXONE INJECTABLS 141 6

9 J01N01 MEROPENEM 125 22

Anti-Infectives
C02F06 AMLODIPINE+TELMISARTAN 90
C10A03 ATORVASTATIN 73 -11 J01C0H AMOXY. & CLAV. LIQUIDS 105 -4
Cardiac

C02G0H TELMISARTAN + HCT 74 8 J01F04 AZITHROMYCIN ORAL SOLIDS 104 5

B01A0E ENOXAPARIN 67 20 J01D0Z CEFTRIAXONE+SULBACTAM 89 13

C01D0B CILNIDIPINE 58 6 J01D0L CEFIXIME ORAL SOL. 87 -1

C01E03 METOPROLOL 56 -8 J01D0I CEFUROXIME ORAL SOLIDS 69 -6

C02F02 ATENOLOL+AMLODIPINE 56 2 J01D0V CEFPODOXIME SOLIDS 75 10

C02F0I METOPROLOL+TELMISARTAN 55 9 J01K05 PIPERACILLIN+TAZOBACTAM 74 10

A02B0Q PANTOPR.+ DOMPERID. 134 5 A10B0Q GLIMEPIRIDE+METFORM. 274 0

A02B0R RABEPRA.+ DOMPERID. 101 1 A10C03 INTER.-ACTING+FAST ACTING 193 -7
A02B0A PANTOPRAZOLE SOLIDS 99 7 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 105 5
17

Anti Diabetic
A07L01 ORAL ELECTROLYTES 54 A10C05 LONG ACTING 87 -7
A07K09 OTHERS 62 12 A10B0D METFORMIN + VILDAGLIPTIN 76 -5
GI

A02B0S ESOMEPR.+ DOMPERID. 62 13 A10C01 FAST ACTING 73 6

A02B01 RANITIDINE ORAL SOLIDS 57 1 A10B0W PIOGLITAZ.+METFORM.+GLIM. 63 1
A09A02 DIGEST. INC. ENZYME LIQUIDS 48 2 A10B07 METFORMIN + SITAGLIPTIN 63 15
A02A05 ANTACID+ANTIFLATU.LIQ 53 17 A10B12 DAPAGLIFLOZIN 48 8
A06A07 MILK OF MAG AND COMB. 49 10 A10B0O METFORMIN + TENELIGLIPTIN 40 -20

• In Cardiac, Enoxaparin posted 20% growth which is highest amongst top therapies
• In AI, Meropenem posted highest growth of 22%
• In GI, Antacid+Antiflatu.Liq. subgroup posted highest growth of 17%
• In Anti diabetic, Glimepride+Metformin registered highest sales of 274 Cr with growth of -0.3%

IQVIA TSA & SSA Dataset Nov'23 18

 Top Therapy Trends
TSA

Value_Nov'23 (Rs. Crs) % Gwth SPLY Value_Nov'23 (Rs. Crs) % Gwth SPLY

R05B01 COUGH PREP. ETHICALS 255 -3 M02A01 NSAIDS 86 -1

R03C0R FORMOTERAL+BUDESONIDE 132 18 N02B05 PARACETAMOL ORAL SOLIDS 81 -1
R03B01 LEVOCETIRIZ.+MONTELU SOLD 122 0 M05C02 CALCITRIOL COMB. 73 -4
Respiratory

R05B05 LEVOSALBUTAMOL & COMB. 111 10 M01A0G PARACE.+ACECLOF.+SERRAPE. 72 12

Pain
R05A02 COLD PREP. LIQUIDS 90 -7 N02B06 PARACETAMOL ORAL LIQUIDS 44 -6
R05B07 CHLORPHNMN+DEXTROMETHRPHN 81 7 M01A0U ACECLOFENAC + PARACETAMOL 40 2
R03C0S IPRATROPIUM + LEVOSALBU. 58 12 N02B0K PARACETAMOL + TRAMADOL 45 1
R05A01 COLD PREP. SOLIDS 56 2 M05B0C COLLAGEN COMB 45 5
R03C02 BUDESONIDE 60 14 N02B07 PARACETAMOL INJECTIONS 47 3
R05B03 CODEINE AND COMB. 25 -52 M01A03 DICLOFENAC INJECTABLES 32 -4

V06E01 FOOD SUPPLEMENTS 190 6 D02A01 EMOLLIENTS,PROTECTIVES 158 2

A12A04 CALCIUM + COLECALCI. SOLI. 102 2 D01C03 ITRACONAZOLE 80 -8
A11F02 MECOBALAMIN COMB. 99 0 D11A09 OTH.DERMATOLOGICAL PREP. 59 3
V06C01 INFANT FORMULAS 101 19 D06A08 MUPIROCIN 37 -13

Derma
A11C02 PLAIN VIT.D 85 5 D02B01 SUNSCREENS 38 17
VMN

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 70 2 D01A02 LULICONAZOLE 35 -9

A12A01 CALCIUM ORAL SOLIDS 47 4 D07D0C CLOBET+MICONAZOL+NEOMYCIN 30 -11
A15A01 APPETITE STIMULANTS 43 -2 D16A0D OTH HAIR CARE PREPS. 31 7
A11A05 OTH. MULTIVIT.-MIN. LIQUIDS 40 6 D02C07 HYDROQU.+TRETI.+MOMETA. 28 -7
V06E05 ADULT WELLNESS 38 -13 D02E01 MINOXIDIL 23 -7

• In Respiratory therapy, Formoteral+Budesonide posted highest growth of 18%

• In Pain market, paracetamol oral solids, liquids & inj contributed ~ 172 crs of sales with -1%, -6% and 3% growth, respectively
• In VMN, food supplements is the top contributing subgroup with 190 Cr of sales posted growth of 6%
• Emollients & protectives registered highest sales of 158 Cr in derma market with 2% growth while the highest growth of 17% is observed in Sunscreens

IQVIA TSA & SSA Dataset Nov'23 19

 Top Therapy Trends
TSA

Value_Nov'23 (Rs. Crs) % Gwth SPLY Value_Nov'23 (Rs. Crs) % Gwth SPLY

N03A0T LEVETIRACETAM 91 6 B03A01 CONV.IRON SOLIDS 112 -2

N06C02 ESCITALOPRAM+CLONAZEPAM 43 9 B03A02 CONV.IRON LIQUID 90 -6
N03A0V GABAPENTIN + NORTRIPTYLIN 40 13 G03D04 DYDROGESTERONE 93 14
Neuro/CNS

Gynaec
N07C01 BETAHISTINE 36 5 G03D03 PROGESTERONE 67 -1
N03A0J OXCARBAZEPINE 27 5 B03A03 CONV.IRON INJ. 63 7
N07A01 PREGABALIN 27 8 G03K02 MIFEPRISTONE+MISOPROSTOL 31 -16
N07A02 PREGABALIN+MECOBALAMIN 24 -6 G03G06 HUMAN MENOPAUSAL GONADOTROP. 36 20
N03A0I NORTRIPTYLINE+PREGABALIN 24 5 G02C01 OTHER GYNAECO.PREP. 30 -5
N03A04 SODIUM VALPROATE ORAL SOLIDS 24 -7 G03G05 HUMAN CHORIONIC GONADOTROP. 25 0
N03A0D CLONAZEPAM 20 -2 G03D02 NORETHISTERONE 26 9

V03D04 SILDENAFIL 47 -7 S01J03 METHYL CELLULOSE/CMC 44 -8

G03J0A DUTASTERIDE + TAMSULOSIN 36 9 S01A0A MOXIFLOXACIN 19 -12
G03J0G DUTASTERIDE + SILODOSIN 34 21 S02A01 OTOLOGICALS 21 -2
G04B09 OTH. UROLOGICAL PREP. 28 3 S01J07 HYALURONIC ACID 15 6

Ophthal
Urology

G03J03 TAMSULOSIN 25 14 S01J0A MACROGOL+PROPYL.GLY&COMB 16 15

G03J0E SILODOSIN 21 13 S01H06 NEPAFENAC 13 -1
G04B01 URINARY ALKALISERS 18 6 S01P04 ANTI-OXIDANTS-OPHTHAL 11 -12
V03D05 TADALAFIL 19 17 S01G0A BRIMONIDINE + TIMOLOL 12 6
G04B0D ALPHA KETOANALOGUE 17 14 S01J04 HPMC 11 0
G04B02 FLAVOXATE 13 6 S02A03 BENZOCAIN+CHLRBUTNL & CMB 7 -5

• In Neuro therapy, Levetiracetam is the top contributing subgroup with 91 Cr of sales posted growth of 6%
• In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~265 Cr of sales to the entire therapy
• In Urology therapy, Dutasteride+Silodosin posted highest growth of 21%
• Methyl Cellulose registered highest sales of 44 cr in ophthal therapy with -8% growth

IQVIA TSA & SSA Dataset Nov'23 20

Key changes
PTR Changes (Top 50 brands) New Introduction

➢ Total number of SKUs with PTR changes in Nov'23 are 2510. ➢ 1123 new packs were Introduced in Nov'23
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Budecort, Asthalin, Cilacar, Thyronorm, Azithral,
Calpol, Manforce, Volini, Zincovit, Augmentin, Betadine, Dolo, Moxikind-
CV, Telma-H, Shelcal, Duphaston, Rantac

New Lab & Corporate Brand Transfer

➢ 38 Corporates & Labs were introduced in Nov'23 dataset ➢ 289 brands transfers registered in Nov’23

IQVIA TSA & SSA Dataset Nov23 21

THANK YOU

22